UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Performing thermal ablations for hepatomas – is it a worthy skill for hepatologists?

Annals of hepatology, 2020-09, Vol.19 (5), p.570-572

2020

Volltextzugriff (PDF)

A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer

American journal of clinical oncology, 2021-09, Vol.44 (9), p.456-462

2021

Volltextzugriff (PDF)

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

The lancet oncology, 2018-07, Vol.19 (7), p.940-952

2018

Volltextzugriff (PDF)

Role of hepatologists in management of hepatocellular carcinoma in the new era of transplant oncology

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.501-501

2020

Volltextzugriff (PDF)

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Clinical cancer research, 2022-06, Vol.28 (12), p.2547-2554

2022

Volltextzugriff (PDF)

Abstract OT-05-01: Fine-sliced neurocognitive assessments and high-resolution neuroimaging biomarkers to diagnose cancer- and chemotherapy-induced cognitive deficits (CCICD) - a pilot study

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-05-01-OT-05-01

2021

Volltextzugriff (PDF)

Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study

Journal of clinical oncology, 2024, Vol.42 (16_suppl), p.4100-4100

2024

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16_suppl), p.4109-4109

2022

Volltextzugriff (PDF)

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study

JOURNAL OF CLINICAL ONCOLOGY, 2021, Vol.39 (15_suppl), p.4074-4074

2021

Volltextzugriff (PDF)

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study

JOURNAL OF CLINICAL ONCOLOGY, 2021, Vol.39 (3_suppl), p.297-297

2021

Volltextzugriff (PDF)

Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

Journal of hepatology, 2020-08, Vol.73, p.S386-S387

2020

Volltextzugriff (PDF)

THU496 - Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

Journal of hepatology, 2020-08, Vol.73, p.S386-S387

2020

Volltextzugriff (PDF)

Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.569-569

2020

Volltextzugriff (PDF)

RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.528-528

2020

Volltextzugriff (PDF)

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology

Liver international, 2021-11, Vol.41 (11), p.2759-2767

2021

Volltextzugriff (PDF)

GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)

Journal of hepatology, 2019-04, Vol.70 (1), p.e46-e46

2019

Volltextzugriff (PDF)

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies

Breast (Edinburgh), 2012-02, Vol.21 (1), p.89-94

2012

Volltextzugriff (PDF)

Durable Responses to Rituximab In Acquired Factor VIII Deficiency

Blood, 2010-11, Vol.116 (21), p.3680-3680

2010

Volltextzugriff (PDF)

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment

Cancer biotherapy & radiopharmaceuticals, 2004-02, Vol.19 (1), p.35-41

2004

Volltextzugriff (PDF)

Assessment of Hepatic Toxicity from Treatment with 90 Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases

Cancer biotherapy & radiopharmaceuticals, 2003-08, Vol.18 (4), p.581-588

2003

Volltextzugriff (PDF)

Assessment of Hepatic Toxicity from Treatment with ^sup 90^Y-SMT 487 (OctreoTher(TM)) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases

Cancer biotherapy & radiopharmaceuticals, 2003-08, Vol.18 (4), p.581

2003

Volltextzugriff (PDF)

Outcome of Transfusion of K:11 Erythrocytes in a Patient with Anti-K11 Antibody

Vox sanguinis, 1998-03, Vol.74 (3), p.205-208

1998

Volltextzugriff (PDF)

Chameleon early dark energy and the Hubble tension

Physical review. D, 2022-03, Vol.105 (6), Article 063535

2022

Volltextzugriff (PDF)

Outcome of Transfusion of K:11 Erythrocytes in a Patient with Anti-K11 Antibody

Vox Sanguinis, 1998, Vol.74 (3), p.205-208

1998

Volltextzugriff (PDF)

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

The New England journal of medicine, 2015-02, Vol.372 (8), p.724-734

2015

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR Complete Journals

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Englisch
(28)
Norwegisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Performing thermal ablations for hepatomas – is it a worthy skill for hepatologists?

A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Role of hepatologists in management of hepatocellular carcinoma in the new era of transplant oncology

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Abstract OT-05-01: Fine-sliced neurocognitive assessments and high-resolution neuroimaging biomarkers to diagnose cancer- and chemotherapy-induced cognitive deficits (CCICD) - a pilot study

Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study

Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

THU496 - Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2

RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro)

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology

GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies

Durable Responses to Rituximab In Acquired Factor VIII Deficiency

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment

Assessment of Hepatic Toxicity from Treatment with 90 Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases

Assessment of Hepatic Toxicity from Treatment with ^sup 90^Y-SMT 487 (OctreoTher(TM)) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases

Outcome of Transfusion of K:11 Erythrocytes in a Patient with Anti-K11 Antibody

Chameleon early dark energy and the Hubble tension

Outcome of Transfusion of K:11 Erythrocytes in a Patient with Anti-K11 Antibody

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Aktive Filter

Suchergebnisse filtern